Literature DB >> 19639016

Proteinuria: Is the ONTARGET renal substudy actually off target?

Piero Ruggenenti, Giuseppe Remuzzi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19639016     DOI： 10.1038/nrneph.2009.109

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  10 in total

1.  Longitudinal studies on the rate of decline in renal function with age.

Authors:  R D Lindeman; J Tobin; N W Shock
Journal:  J Am Geriatr Soc       Date:  1985-04       Impact factor: 5.562

2.  Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors:  Mahboob Rahman; Sara Pressel; Barry R Davis; Chuke Nwachuku; Jackson T Wright; Paul K Whelton; Joshua Barzilay; Vecihi Batuman; John H Eckfeldt; Michael Farber; Mario Henriquez; Nelson Kopyt; Gail T Louis; Mohammad Saklayen; Carol Stanford; Candace Walworth; Harry Ward; Thomas Wiegmann
Journal:  Arch Intern Med       Date:  2005-04-25

3.  Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease.

Authors:  Regina Kunz; Chris Friedrich; Marcel Wolbers; Johannes F E Mann
Journal:  Ann Intern Med       Date:  2007-11-05       Impact factor: 25.391

4.  Re-examining RAS-blocking treatment regimens for abrogating progression of chronic kidney disease.

Authors:  Murray Epstein
Journal:  Nat Clin Pract Nephrol       Date:  2008-11-04

5.  Role of remission clinics in the longitudinal treatment of CKD.

Authors:  Piero Ruggenenti; Elena Perticucci; Paolo Cravedi; Vincenzo Gambara; Marco Costantini; Sanjib Kumar Sharma; Annalisa Perna; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2008-03-19       Impact factor: 10.121

6.  Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

Authors:  Johannes F E Mann; Roland E Schmieder; Matthew McQueen; Leanne Dyal; Helmut Schumacher; Janice Pogue; Xingyu Wang; Aldo Maggioni; Andrzej Budaj; Suphachai Chaithiraphan; Kenneth Dickstein; Matyas Keltai; Kaj Metsärinne; Ali Oto; Alexander Parkhomenko; Leopoldo S Piegas; Tage L Svendsen; Koon K Teo; Salim Yusuf
Journal:  Lancet       Date:  2008-08-16       Impact factor: 79.321

7.  Retarding progression of chronic renal disease: the neglected issue of residual proteinuria.

Authors:  Piero Ruggenenti; Annalisa Perna; Giuseppe Remuzzi
Journal:  Kidney Int       Date:  2003-06       Impact factor: 10.612

Review 8.  Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection.

Authors:  Norberto Perico; Ariela Benigni; Giuseppe Remuzzi
Journal:  Nat Rev Drug Discov       Date:  2008-10-10       Impact factor: 84.694

9.  Proteinuria and the risk of developing end-stage renal disease.

Authors:  Kunitoshi Iseki; Yoshiharu Ikemiya; Chiho Iseki; Shuichi Takishita
Journal:  Kidney Int       Date:  2003-04       Impact factor: 10.612

Review 10.  Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis.

Authors:  Juan P Casas; Weiliang Chua; Stavros Loukogeorgakis; Patrick Vallance; Liam Smeeth; Aroon D Hingorani; Raymond J MacAllister
Journal:  Lancet       Date:  2005-12-10       Impact factor: 79.321
  10 in total
  13 in total

Review 1.  Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis.

Authors:  Min Jun; Tanvir Chowdhury Turin; Mark Woodward; Vlado Perkovic; Hiddo J Lambers Heerspink; Braden J Manns; Marcello Tonelli; Brenda R Hemmelgarn
Journal:  J Am Soc Nephrol       Date:  2015-01-02       Impact factor: 10.121

2.  Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial.

Authors:  Piero Ruggenenti; Annalisa Perna; Marcello Tonelli; Giacomina Loriga; Nicola Motterlini; Nadia Rubis; Franca Ledda; Stefano Rota; Andrea Satta; Antonio Granata; Giovanni Battaglia; Francesco Cambareri; Salvatore David; Flavio Gaspari; Nadia Stucchi; Sergio Carminati; Bogdan Ene-Iordache; Paolo Cravedi; Giuseppe Remuzzi
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-29       Impact factor: 8.237

Review 3.  Improving the efficacy of RAAS blockade in patients with chronic kidney disease.

Authors:  Hiddo J Lambers Heerspink; Martin H de Borst; Stephan J L Bakker; Gerjan J Navis
Journal:  Nat Rev Nephrol       Date:  2012-12-18       Impact factor: 28.314

Review 4.  The RAAS in the pathogenesis and treatment of diabetic nephropathy.

Authors:  Piero Ruggenenti; Paolo Cravedi; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2010-05-04       Impact factor: 28.314

5.  Achieving remission of proteinuria in childhood CKD.

Authors:  Piero Ruggenenti; Paolo Cravedi; Antonietta Chianca; MariaRosa Caruso; Giuseppe Remuzzi
Journal:  Pediatr Nephrol       Date:  2016-10-04       Impact factor: 3.714

Review 6.  Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis.

Authors:  Hiddo J Lambers Heerspink; Tobias F Kröpelin; Jarno Hoekman; Dick de Zeeuw
Journal:  J Am Soc Nephrol       Date:  2014-11-24       Impact factor: 10.121

Review 7.  Role of angiotensin II in the development of nephropathy and podocytopathy of diabetes.

Authors:  Kirk N Campbell; Leopoldo Raij; Peter Mundel
Journal:  Curr Diabetes Rev       Date:  2011-01

8.  The role of renin angiotensin system inhibition in kidney repair.

Authors:  Irene M van der Meer; Paolo Cravedi; Giuseppe Remuzzi
Journal:  Fibrogenesis Tissue Repair       Date:  2010-05-04

Review 9.  The effect of RAAS blockade on the progression of diabetic nephropathy.

Authors:  Sara S Roscioni; Hiddo J Lambers Heerspink; Dick de Zeeuw
Journal:  Nat Rev Nephrol       Date:  2013-12-03       Impact factor: 28.314

10.  The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease.

Authors:  Mai Yanagi; Kouichi Tamura; Tetsuya Fujikawa; Hiromichi Wakui; Tomohiko Kanaoka; Masato Ohsawa; Kengo Azushima; Akinobu Maeda; Hiroyuki Kobori; Satoshi Umemura
Journal:  Hypertens Res       Date:  2012-11-15       Impact factor: 3.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.